Minimum custom amount to enter is AED 2
By donating, you agree to the Privacy Policy and Terms of Service
In a major vote of confidence towards the Sinopharm vaccine, the UAE’s Ministry of Health and Prevention has announced the results and the official registration of Beijing Institute of Biological Product’s inactivated COVID-19 vaccine.
According to Wam.ae, MOHAP in collaboration with Department of Health Abu Dhabi (DOH) has reviewed Sinopharm CNBG’s analysis of the phase III trials, which shows Beijing Institute of Biological Product’s inactivated vaccine to have 86% efficacy against COVID-19 infection.
Phase 1 and 2 of the Sinopharm vaccine were completed in China, and the UAE was chosen for its diverse population by the pharmaceutical company, in alliance with the Abu Dhabi Government and Abu Dhabi-based artificial intelligence company G42 Healthcare.
The analysis also shows the vaccine to have 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease. Furthermore, the analysis shows NO serious safety concerns.
This vaccine was granted Emergency Use Authorisation (EUA) since September by MOHAP to protect frontline workers most at risk of COVID-19.
31,000 volunteers from 125 nationalities put themselves forward for the phase III trials and the vaccination program has effectively safeguarded the UAE frontline workers, according to the report.
Those who fail to comply with the country’s strict COVID-19 regulations will be subject to face a penalty of AED3,000.
Minimum custom amount to enter is AED 2
By donating, you agree to the Privacy Policy and Terms of Service